Sunesis Advisors, LLC - DECIPHERA PHARMACEUTICALS IN ownership

DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 145 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.2%.

Quarter-by-quarter ownership
Sunesis Advisors, LLC ownership history of DECIPHERA PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$1,224,923
-17.7%
96,2990.0%0.87%
-18.9%
Q1 2023$1,487,820
-5.7%
96,2990.0%1.07%
+6.0%
Q4 2022$1,578,341
-11.4%
96,2990.0%1.01%
-17.6%
Q3 2022$1,782,000
+40.8%
96,2990.0%1.23%
+49.0%
Q2 2022$1,266,000
+41.8%
96,2990.0%0.82%
+59.2%
Q1 2022$893,000
-5.1%
96,2990.0%0.52%
-25.1%
Q4 2021$941,000
-71.2%
96,2990.0%0.69%
-72.7%
Q3 2021$3,272,000
-7.2%
96,2990.0%2.53%
-6.4%
Q2 2021$3,526,000
-18.3%
96,2990.0%2.70%
-21.8%
Q1 2021$4,318,000
-21.4%
96,2990.0%3.45%
-22.4%
Q4 2020$5,496,000
+11.3%
96,2990.0%4.45%
+1.2%
Q3 2020$4,940,000
-14.1%
96,2990.0%4.39%
-17.0%
Q2 2020$5,751,000
+45.0%
96,2990.0%5.29%
+32.7%
Q1 2020$3,965,000
-33.9%
96,2990.0%3.99%
-26.9%
Q4 2019$5,994,000
+83.4%
96,2990.0%5.46%
+60.8%
Q3 2019$3,268,000
+50.5%
96,2990.0%3.39%
+45.8%
Q2 2019$2,172,000
-2.8%
96,2990.0%2.33%
+3.3%
Q1 2019$2,235,000
+10.6%
96,2990.0%2.25%
+2.1%
Q4 2018$2,021,000
-45.8%
96,2990.0%2.20%
-41.4%
Q3 2018$3,729,000
-1.6%
96,2990.0%3.76%
-19.0%
Q2 2018$3,789,00096,2994.65%
Other shareholders
DECIPHERA PHARMACEUTICALS IN shareholders Q4 2022
NameSharesValueWeighting ↓
New Leaf Venture Partners, L.L.C. 1,209,571$69,030,00015.95%
SV Health Investors, LLC 449,951$25,679,00012.37%
Sunesis Advisors, LLC 96,299$5,496,0004.45%
Redmile Group, LLC 4,437,968$253,275,0003.07%
Consonance Capital Management LP 484,671$27,660,0002.58%
SECTORAL ASSET MANAGEMENT INC 488,842$27,898,0001.97%
Opaleye Management Inc. 222,000$12,670,0001.66%
Eversept Partners, LP 246,240$14,052,9171.65%
SILVERARC CAPITAL MANAGEMENT, LLC 38,620$2,204,0001.28%
Avoro Capital Advisors LLC 1,300,000$74,191,0001.28%
View complete list of DECIPHERA PHARMACEUTICALS IN shareholders